Breakthrough in cardiology:
- New life-saving therapy helps people with weak hearts
A groundbreaking international study headed by Danish researchers has just been published in the esteemed Journal of The American College of Cardiology, HEART FAILURE.
The Q-Symbio study points to a whole new adjuvant in the treatment of chronic heart failure. With supplements of a natural compound that boosts the energy turnover in the heart, it is now possible to make the heart stronger and improve survival among patients with chronic heart failure.
A total of 420 heart failure patients participated in the study. They were randomly assigned to receive either 300 mg of coenzyme Q10 (Bio-Quinone Q10) daily or identical dummy capsules (placebo). The treatment was administered as an add-on to their prescribed regimen of heart failure drugs.
43% fewer deaths
Among those who were given coenzyme Q10, there were 43% fewer heart-related deaths and complications compared to those who were given placebo.
Head of research, Chief Physician Svend Aage Mortensen, from the The Heart Center of Copenhagen University Hospital, describes the new study as a potential shift of paradigm in the treatment of chronic heart failure.
“Conventional drug therapy aims at inhibiting various hormonal factors that are predominant in heart failure and which strain the heart. By adding coenzyme Q10 to the normal drug therapy, the energy turnover of the heart muscle is improved and the heart muscle gets increased strength which, in turn, improves symptoms of the disease,” Dr. Mortensen explains.
Source: Journal of the American College of Cardiology, HEART FAILURE online October 2014